van Heyningen V, Cohen B B, Deane D L, Gray C, Steel C M
Tissue Antigens. 1981 Feb;17(2):149-61. doi: 10.1111/j.1399-0039.1981.tb00679.x.
The Burkitt lymphoma (BL)-derived, HLA-DR antigen positive B cell line, EB1, is a consistently low stimulator in MLC. A rabbit antiserum raised against the strongly stimulating BL line DAUDI, after appropriate absorption with EB1, inhibits MLC stimulation by both B cell lines and allogeneic lymphocytes, whilst lectin-induced proliferation is not significantly affected. Indirect immunofluorescence and 125I-staphylococcal protein A binding to cells pre-incubated with this antiserum suggest that the antigen is present on both peripheral B and T cells, as well as on B lymphoblastoid and myeloma lines. We suggest that this antiserum is directed against lymphocyte activating determinant(s) (LADs) and that these are distinct from the serologically defined DR antigens.
源自伯基特淋巴瘤（BL）的HLA - DR抗原阳性B细胞系EB1，在混合淋巴细胞培养（MLC）中始终是低刺激物。用强刺激的BL细胞系DAUDI免疫家兔制备的抗血清，经EB1适当吸收后，可抑制这两种B细胞系和同种异体淋巴细胞的MLC刺激，而凝集素诱导的增殖则未受到显著影响。间接免疫荧光以及125I - 葡萄球菌蛋白A与用该抗血清预孵育的细胞结合表明，该抗原存在于外周B细胞和T细胞以及B淋巴母细胞系和骨髓瘤细胞系上。我们认为该抗血清针对的是淋巴细胞激活决定簇（LADs），并且这些决定簇与血清学定义的DR抗原不同。
